A multi-parameter response prediction model for rituximab in rheumatoid arthritis - 28/02/18
, Jérémie Sellam b, 1, Rabia Agca a, c, Saskia Vosslamber d, Birgit I. Witte e, Michel Tsang-A-Sjoe a, Elise Mantel a, Johannes W. Bijlsma a, c, Alexandre E. Voskuyl a, Mike T. Nurmohamed a, c, Cornelis L. Verweij d, 2, 3, Xavier Mariette f, 2Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 8 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objectives |
To validate the IFN response gene (IRG) set for the prediction of non-response to rituximab in rheumatoid arthritis (RA) and assess the predictive performance upon combination of this gene set with clinical parameters.
Methods |
In two independent cohorts of 93 (cohort I) and 133 (cohort II) rituximab-starting RA patients, baseline peripheral blood expression of eight IRGs was determined, and averaged into an IFN score. Predictive performance of IFN score and clinical parameters was assessed by logistic regression. A multivariate prediction model was developed using a forward stepwise selection procedure. Patients with a decrease in disease activity score (ΔDAS28)≥1.8 after 6 months of therapy were considered responders.
Results |
The mean IFN score was higher in non-responders compared to responders in both cohorts, but this difference was most pronounced in patients who did not use prednisone, as described before. Univariate analysis in cohort I showed that baseline DAS28, IFN score, DMARD use and negativity for IgM-RF and/or ACPA were associated with rituximab non-response. The multivariate model consisted of DAS28, IFN score and DMARD use, which showed an area under the curve (AUC) of 0.82. In cohort II, this model revealed a comparable AUC in PREDN-negative patients (0.78), but AUC in PREDN-positive patients was significantly lower (0.63), which seemed due to effect modification of the IFN score by prednisone.
Conclusions |
Combination of predictive parameters provided a promising model for the prediction of non-response to rituximab, with possibilities for optimization via definition of the exact interfering effect of prednisone on IFN score.
Trial registration (Cohort II, SMART trial) |
NCT01126541, registered 18 May 2010.
Le texte complet de cet article est disponible en PDF.Keywords : Rheumatoid arthritis, Rituximab, Prediction, Type I interferon
Plan
Vol 85 - N° 2
P. 219-226 - mars 2018 Retour au numéro
Article précédent
- Precision and sources of variability in the assessment of rheumatoid arthritis erosions by HRpQCT
- Nada Ibrahim-Nasser, Hubert Marotte, Antoine Valery, Carine Salliot, Hechmi Toumi, Eric Lespessailles
- Time-course of ultrasound abnormalities of major salivary glands in suspected Sjögren's syndrome
- Pierre Gazeau, Divi Cornec, Sandrine Jousse-Joulin, Dewi Guellec, Alain Saraux, Valérie Devauchelle-Pensec
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?